Inventor · disambiguated record
Dominique Jean-Pierre Mabire
Also filed as: MABIRE DOMINIQUE · MABIRE DOMINIQUE JEAN-PIERRE
21 granted patents·2 pending applications·199 citations·filing 1995–2013
95Inventor score
Files withJANSSEN PHARMACEUTICA NV15MABIRE DOMINIQUE JEAN-PIERRE5INST CURIE1JANSSEN CILAG S A1MABIRE DOMINIQUE1
Top patents by PatentIndex Score
23 records- 0191US6486187B1N-[4-(heteroarylmethyl)phenyl]-heteroarylaminesJANSSEN PHARMACEUTICA NV·Filed 2000·Granted Nov 26, 2002·31 cites·10 claims
- 0285US7928104B27-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitorsMABIRE DOMINIQUE JEAN-PIERRE·Filed 2004·Granted Apr 19, 2011·25 cites·12 claims
- 0384US7115630B2Metabotropic glutamate receptor antagonistsJANSSEN PHARMACEUTICA NV·Filed 2001·Granted Oct 3, 2006·21 cites·10 claims
- 0483US6833375B2N-[4-(heteroarylmethyl)phenyl]-heteroarylaminesJANSSEN PHARMACEUTICA NV·Filed 2002·Granted Dec 21, 2004·13 cites·7 claims
- 0582US7652014B2Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Jan 26, 2010·17 cites·28 claims
- 0682US7179825B2Retinoic acid mimetic anilidesJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Feb 20, 2007·4 cites·10 claims
- 0780US7879857B26-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Feb 1, 2011·11 cites·10 claims
- 0880US7629468B2Metabotropic glutamate receptor antagonistsJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Dec 8, 2009·6 cites·9 claims
- 0976US6319939B1Retinoic acid mimetic anlidesJANSSEN PHARMACEUTICA NV·Filed 1998·Granted Nov 20, 2001·29 cites·13 claims
- 1075US6936626B2Retinoic acid mimetic anilidesJANSSEN PHARMACEUTICA NV·Filed 2001·Granted Aug 30, 2005·6 cites·11 claims
- 1174US7579352B2Retinoic acid mimetic anilidesJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Aug 25, 2009·1 cites·11 claims
- 1274US7115608B2Pyridinone and pyridinethione derivatives having HIV inhibiting propertiesINST CURIE·Filed 2001·Granted Oct 3, 2006·8 cites·9 claims
- 1373US6124330AN-[4-(Heteroarylmethyl)phenyl]-heteroarylaminesJANSSEN CILAG S A·Filed 1997·Granted Sep 26, 2000·25 cites·12 claims
- 1468US7205312B2N-[4-(heteroarylmethyl)phenyl]-heteroarylaminesJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Apr 17, 2007·2 cites·11 claims
- 1562US7378433B2N-[4-(heteroarylmethyl)phenyl]-heteroarylaminesJANSSEN PHARMACEUTICA NV·Filed 2006·Granted May 27, 2008·0 cites·24 claims
- 1659US9115084B26-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2013·Granted Aug 25, 2015·0 cites·1 claims
- 1759US2007105858A1Retinoic acid mimetic anilidesMABIRE DOMINIQUE·Filed 2006·Application pending·0 cites
- 1855US8450486B26-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitorsMABIRE DOMINIQUE JEAN-PIERRE·Filed 2011·Granted May 28, 2013·0 cites·1 claims
- 1955US7855207B26-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Dec 21, 2010·0 cites·5 claims
- 2053US8071612B26-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitorsMABIRE DOMINIQUE JEAN-PIERRE·Filed 2010·Granted Dec 6, 2011·0 cites·5 claims
- 2146US8524714B27-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitorsMABIRE DOMINIQUE JEAN-PIERRE·Filed 2011·Granted Sep 3, 2013·0 cites·1 claims
- 2244US2011230491A16-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitorsMABIRE DOMINIQUE JEAN-PIERRE·Filed 2010·Application pending·0 cites
- 2330US5922734A6- triazolyl 3-(trifluoromethyl)phenyl!methyl!-2-quinolines and -quinolinethionesJANSSEN PHARMACEUTICA NV·Filed 1995·Granted Jul 13, 1999·0 cites·16 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →